WO2022241707A1 - Extrait d'huile riche en curcuminoïdes, procédé de préparation et utilisations associées dans le traitement de maladies associées à des lésions neuronales - Google Patents

Extrait d'huile riche en curcuminoïdes, procédé de préparation et utilisations associées dans le traitement de maladies associées à des lésions neuronales Download PDF

Info

Publication number
WO2022241707A1
WO2022241707A1 PCT/CN2021/094802 CN2021094802W WO2022241707A1 WO 2022241707 A1 WO2022241707 A1 WO 2022241707A1 CN 2021094802 W CN2021094802 W CN 2021094802W WO 2022241707 A1 WO2022241707 A1 WO 2022241707A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
curcuminoid
extract
rich
curcuminoids
Prior art date
Application number
PCT/CN2021/094802
Other languages
English (en)
Inventor
Tzung-Yan LEE
Hen-Hong Chang
Wei-Han CHIANG
Original Assignee
Lee Tzung Yan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lee Tzung Yan filed Critical Lee Tzung Yan
Priority to PCT/CN2021/094802 priority Critical patent/WO2022241707A1/fr
Publication of WO2022241707A1 publication Critical patent/WO2022241707A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/02—Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
    • A23D9/04—Working-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Definitions

  • the present disclosure in general relates to the field of disease treatment. More particularly, the present disclosure relates to a curcuminoid-rich extract, its preparation method and uses in the treatment of diseases associated with neuron injury (e.g., dopamine neuron injury) .
  • neuron injury e.g., dopamine neuron injury
  • Curcuma longa a member of the ginger family (Zingiberaceae) , has rhizomes below the ground. Curcuma longa has been used for thousands of years as a remedy in folk medicine for the cure of a wide variety of illnesses, such as inflammation, infectious diseases, and gastric, hepatic, and blood disorders.
  • Curcuminoids such as curcumin are natural polyphenol compounds derived from Curcuma longa, their biological activities have been extensively investigated, including for their role as nutraceuticals with potential against cancer, diabetes and inflammation.
  • the present disclosure aims at providing a curcuminoid-rich extract of Curcuma longa, and a method of producing the same, in which the curcuminoids in the curcuminoid-rich extract produced by the present method has more than 5-folds of bisdemethoxycurcumin as compared to that in the extract produced by an existing known method.
  • the present disclosure is directed to novel method for producing a curcuminoid-rich oil extract, the thus produced curcuminoid-rich oil extract and its use in the treatment of diseases associated with neuron injury, particularly dopaminergic neuron injury.
  • the first aspect of the present disclosure is directed to a method of producing a curcuminoid-rich oil extract.
  • the method includes extracting dried Curcuma longa powders with an oil, thereby producing the curcuminoid-rich oil extract, in which the curcuminoids consist of 25-30% (wt%) of bisdemethoxycurcumin, 25-30% (wt%) of demethoxycurcumin, and 40-50%(wt%) of curcumin.
  • the extraction is performed by, (i) mixing the dried Curcuma longa powders with the oil; and (ii) double boiling the oil mixture of the step (i) under ultra-sound vibrations.
  • the oil suitable for mixing with dried Curcuma longa powders in the step (i) is an edible vegetable oil.
  • exemplary edible vegetable oil includes, but is not limited to, coconut oil, corn oil, canola oil, cottonseed oil, olive oil, palm oil, peanut oil, rapeseed oil, sunflower oil, sesame oil, soybean oil, and nut oil.
  • the dried Curcuma longa powders is extracted with olive oil.
  • the double boiling in the step (ii) is performed by heating the oil mixture sequentially at 50°C for 30 min, 60°C for 30 min, and 80°C for 30 min; in which each heating is accompanied with the ultra-sound vibrations about 25-35 kHz in frequency.
  • the dried Curcuma longa powders are prepared by, (a) cutting the rhizome of a fresh Curcuma longa into slices; (b) drying the slices of the step (a) at 55°C; and (c) grounding the dried slices of the step (b) into powders via a ball-miller.
  • the second aspect of the present disclosure is directed to a curcuminoid-rich oil extract produced by the present method.
  • the curcuminoid-rich oil extract comprises curcuminoids dissolved in the oil, in which the curcuminoids consist of 25-30% (wt%) of bisdemethoxycurcumin, 25-30% (wt%) of demethoxycurcumin, and 40-50% (wt%) of curcumin.
  • the third aspect of the present disclosure is directed to a novel use of the curcuminoid-rich oil extract produced by the present method, in which the curcuminoid-rich oil extract is found to suppress the expression of proteins associated with neuron damage in brain tissues, including substantia nigra pars compacta (SNpc) , striatum, hippocampus, and amygdala; thus are useful for the treatment of diseases associated with neuron injury.
  • SNpc substantia nigra pars compacta
  • striatum striatum
  • hippocampus hippocampus
  • amygdala amygdala
  • the curcuminoid-rich oil extract comprises curcuminoids dissolved in an oil, and the curcuminoids consist of 25-30% (wt%) of bisdemethoxycurcumin, 25-30% (wt%) of demethoxycurcumin, and 40-50% (wt%) of curcumin.
  • Examples of the disease treatable by the present curcuminoid-rich oil extract include, but are not limited to, dementia with Lewy bodies (DLB) , Parkinson’s disease (PD) or Alzheimer disease (AD) .
  • DLB dementia with Lewy bodies
  • PD Parkinson’s disease
  • AD Alzheimer disease
  • the subject suitable for receiving the curcuminoid-rich oil extract produced by the present method is a mammal; preferably, a human.
  • UCP4 uncoupling receptor 4
  • extract encompasses crude extracts as well as processed or refined extract.
  • crude extracts are prepared by a simple extraction in which dried root powders of the selected plant are brought into contact with an extractant (i.e., an oil) in the presence of heat and/or ultrasound vibrations.
  • an extractant i.e., an oil
  • the thus-produced crude extract is subjected to one or more separation and/or purification steps to obtain purified, processed or refined extracts.
  • the extract may be in liquid form, such as a solution, a concentrate, or a distillate.
  • weight percentage refers to the weight percentage of an ingredient (e.g., the bisdemethoxycurcumin, demethoxycurcumin, or curcumin of the present curcuminoid-rich extract) in a mixture containing the ingredient.
  • the weight percentage (wt %) is calculated as the weight of the ingredient divided by the total weight of the mixture expressed in percentage and/or decimal.
  • the term “treat, ” “treating” and “treatment” are interchangeable, and encompasses partially or completely preventing, ameliorating, mitigating and/or managing a symptom, a secondary disorder or a condition associated with neuron injury, particularly dopaminergic neuron injury.
  • the term “treating” as used herein refers to application or administration of the of the present disclosure to a subject, who has a symptom, a secondary disorder or a condition associated with neuron injury, with the purpose to partially or completely prevent, alleviate, ameliorate, relieve, delay onset of, inhibit progression of, reduce severity of, and/or reduce incidence of one or more symptoms, secondary disorders or features associated with neuron injury.
  • Treatment may be administered to a subject who exhibits only early signs of such symptoms, disorder, and/or condition for the purpose of decreasing the risk of developing the symptoms, secondary disorders, and/or conditions associated with neuron injury.
  • Treatment is generally “effective” if one or more symptoms or clinical markers associated with neuron injury are reduced.
  • a treatment is “effective” if the progression of a symptom, disorder or condition is reduced or halted.
  • an effective amount designate the quantity of a component which is sufficient to yield a desired response.
  • the effective amount is also one in which any toxic or detrimental effects of the component are outweighed by the therapeutically beneficial effects.
  • An effective amount of an agent is not required to cure a disease or condition but will provide a treatment for a disease or condition such that the onset of the disease or condition is delayed, hindered or prevented, or the disease or condition symptoms are ameliorated.
  • the effective amount may be divided into one, two, or more doses in a suitable form to be administered at one, two or more times throughout a designated time period.
  • Effective amount will vary with such factors as the particular condition being treated, the physical condition of the patient (e.g., the patient's body mass, age, or gender) , the type of mammal or animal being treated, the duration of the treatment, the nature of concurrent therapy (if any) , and the specific formulations employed and the structure of the compounds or its derivatives. Effective amount may be expressed, for example, in grams, milligrams or micrograms or as milligrams per kilogram of body weight (mg/Kg) .
  • the effective amount can be expressed in the concentration of the active component (e.g., bisdemethoxycurcumin, demethoxycurcumin, or curcumin of the present curcuminoid-rich oil extract) , such as molar concentration, mass concentration, volume concentration, molality, mole fraction, mass fraction and mixing ratio.
  • the active component e.g., bisdemethoxycurcumin, demethoxycurcumin, or curcumin of the present curcuminoid-rich oil extract
  • HED human equivalent dose
  • FDA US Food and Drug Administration
  • subject and patient are used interchangeably herein, and are intended to mean an animal including the human species that is treatable by the curcuminoid-rich oil extract and/or method of the present invention.
  • subject or patient intended to refer to both the male and female gender unless one gender is specifically indicated. Accordingly, the term “subject” or “patient” comprises any mammal, which may benefit from the curcuminoid-rich oil extract or the treatment method of the present disclosure.
  • a “subject” or “patient” include, but are not limited to, a human, rat, mouse, guinea pig, monkey, pig, goat, cow, horse, dog, cat, bird and fowl.
  • the subject is a human.
  • the first aspect of the present disclosure aims at providing a method for producing a curcuminoid-rich extract.
  • the method includes extracting Curcuma longa with an oil, so as to produce a curcuminoid-rich oil extract, in which the curcuminoids are dissolved in the oil, and the curcuminoids consist of 25-30% (wt%) of bisdemethoxycurcumin, 25-30% (wt%) of demethoxycurcumin, and 40-50% (wt%) of curcumin.
  • the rhizome of a fresh Curcuma longa is cut into slices about 0.2 cm in thickness, which are dried at 55°C, and then grounded into powders, such as with the aid of a ball-miller. Additionally or alternatively, the grounded powders may be filtered through a filter about 400 meshes to give Curcuma longa powders independently less than 38 ⁇ m in diameter.
  • the thus produced dried Curcuma longa powders are mixed with an edible vegetable oil in a weight (g) to volume (L) ratio of 10: 1 to 1: 10, such as 10: 1, 9: 1, 8: 1, 7: 1, 6: 1, 5: 1, 4: 1, 3: 1, 2: 1, 1: 1, 9: 2, 9: 3, 9: 4, 9: 5, 9: 6, 9: 7, 9: 8, 9: 10, 8: 3, 8: 5, 8: 6, 8: 7, 8: 9, 8: 10, 7: 2, 7: 3, 7: 4, 7: 5, 7: 6, 7: 8, 7: 9, 7: 10, 6: 4, 6: 5, 6: 7, 6: 8, 6: 9, 6: 10, 5: 2, 5: 3, 5: 4, 5: 6, 5: 7, 5: 8, 5: 9, 5: 10, 4: 1, 4: 3, 4: 5, 4: 6, 4: 7, 4: 8, 4: 9, 4: 10, 3: 1, 3: 7, 3: 8, 3: 10, 2: 9, 2: 7, 1: 7, 1: 8, 1: 9, and 1: 10; preferably, in a weight (g) to volume (L) ratio of 10:
  • Exemplary edible vegetable oil suitable for use in the present method includes, but is not limited to, coconut oil, corn oil, canola oil, cottonseed oil, olive oil, palm oil, peanut oil, rapeseed oil, sunflower oil, sesame oil, soybean oil, and nut oil.
  • the dried Curcuma longa powders is extracted with olive oil.
  • the oil mixture is double boiled first at 50°C for 30 min, then at 60°C for 30 min, and finally 80°C for 30 min, respectively; with each heating being conducted in the presence of ultra-sound vibrations about 25-35 kHz in frequency, such as about 28 kHz.
  • the step of “double boiling” referred to heating the oil mixture of dried Curcuma longa powders and oil (e.g., olive oil) indirectly, that is, by placing the mixture in a first container, which is placed over a second container pre-filled with sufficient amount of water, then applied direct heat to the second container until the temperature in the second container reached a pre-designated temperature (e.g., 50, 60 or 80°C) , which is then maintained for a pre-described period (e.g., 30 min) .
  • a pre-designated temperature e.g., 50, 60 or 80°C
  • a pre-described period e.g. 30 min
  • ultrasound wave vibrations about 25-35 kHz, such as 25, 26, 27, 28, 30, 31, 32, 33, 34 and 35 kHz are applied to the first container during the entire double boiling period.
  • the thus produced oil extract was termed “ATG-235 solution” in the present disclosure.
  • the ATG-235 solution produced by the present method described above is rich in curcuminoids, in which the curcuminoids in the ATG-235 solution consist of 25-30% (wt%) of bisdemethoxycurcumin, 25-30% (wt%) of demethoxycurcumin, and 40-50% (wt%) of curcumin.
  • the ATG-235 solution consisted of about 26.7% (wt%) of bisdemethoxycurcumin, about 28.8% (wt%) of demethoxycurcumin, and about 44.5% (wt%) of curcumin; while the curcuminoids in the Curcuma longa extract produced by a known conventional process consist 5.7% (wt%) of bisdemethoxycurcumin, 24.1% (wt%) of demethoxycurcumin, and 70.8% (wt%) of curcumin.
  • ATG-235 solution produced by the present method is rich in bisdemethoxycurcumin and low in curcumin, with bisdemethoxycurcumin being about 5-folds more than that produced by the known method, and curcumin being about half of that produced by the known method.
  • the present curcuminoid-rich extract or the ATG-235 solution may be formulated with one or more appropriate pharmaceutically acceptable carriers or excipients, and may be formulated into dosage forms suitable for oral and parenteral administration.
  • the ATG-235 solution of the present disclosure may be administered alone or in combination with other known pharmaceutically active agent to treat diseases associated with neuron injury.
  • One of skilled person in the art is familiar with the various dosage forms that are suitable for use in each route.
  • the ATG-235 solution of the present disclosure is formulated into a liquid dosage form for parenteral administration, such as injection, which includes, but is not limited to, subcutaneous, intramuscular, intraperitoneal and intravenous injection.
  • parenteral administration such as injection
  • the ATG-235 solution may be formulated in oily or aqueous vehicles, and may contain formulatoary agents and/or flavoring agents. They may be presented in sterile ampoules or vials.
  • the ATG-235 solution of the present disclosure is formulated into liquid dosage forms for oral administration.
  • the liquid dosage formulations may also be filled into soft gelatin capsules.
  • the liquid may include a solution, suspension, emulsion, micro-emulsion, precipitate or any desired liquid media carrying the active ingredients of the present ATG-235 solution.
  • the liquid may be designed to improve the solubility of the active ingredients of the present ATG-235 solution to form a drug-containing emulsion or disperse phase upon release.
  • a further aspect of the present disclosure is directed to a novel use of the present curcuminoid-rich oil extract, which is found to suppress the expression of proteins associated with neuron injury in brain tissues, including substantia nigra pars compacta (SNpc) , striatum, hippocampus, and amygdala; thus are useful as medicaments or dietary supplements for the treatment of diseases associated with neuron injury.
  • SNpc substantia nigra pars compacta
  • striatum striatum
  • hippocampus hippocampus
  • amygdala amygdala
  • the curcuminoid-rich oil extract comprises curcuminoids dissolved in an oil, and the curcuminoids consist of 25-30% (wt%) of bisdemethoxycurcumin, 25-30% (wt%) of demethoxycurcumin, and 40-50% (wt%) of curcumin.
  • the present curcuminoid-rich oil extract or ATG-235 solution is orally or parenterally administered to a subject suffering from diseases associated with neuron injury in a single dose or in multiple doses (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or more doses) .
  • Examples of the disease treatable by the present curcuminoid-rich oil extract include, but are not limited to, dementia with Lewy bodies (DLB) , Parkinson’s disease (PD) or Alzheimer disease (AD) .
  • DLB dementia with Lewy bodies
  • PD Parkinson’s disease
  • AD Alzheimer disease
  • the subject suitable for receiving the curcuminoid-rich oil extract produced by the present method is a mammal; preferably, a human.
  • the subject is a mouse.
  • about 1-100 mg/Kg body weight per dose of the present curcuminoid-rich oil extract is administered to the subject; preferably, about 10-90 mg/Kg body weight per dose of the present ATG-235 solution is administered to the subject; more preferably, 50-70 mg of the present ATG-235 solution per Kg body weight per dose is sufficient to elicit a therapeutic effect on neuron injury in the subject.
  • the effective amount of the present ATG-235 solution suitable for use in a human subject may be in the range of 0.08-8 mg/Kg body weight per dose for human; preferably, 0.8-8 mg/Kg body weight per dose.
  • the curcuminoid-rich oil extract of the present disclosure is administered to the subject daily for at least 7 days; for example, being administered to the subject daily for 7, 8, 9, 10, 11, 12, 13, 14, or more day. In one specific example, the curcuminoid-rich oil extract of the present disclosure is administered to the subject daily for 14 days.
  • the skilled artisan or clinical practitioner may adjust the dosage or regime in accordance with the physical condition of the patient or the severity of the diseases.
  • the present curcuminoid-rich oil extract can be applied to the subject, alone or in combination with additional therapies that have some beneficial effects on the prevention or treatment of muscle atrophy.
  • the present curcuminoid-rich oil extract can be applied to the subject before, during, or after the administration of the additional therapies.
  • the subject treatable by the present curcuminoid-rich oil extract and/or method is a mammal, for example, human, mouse, rat, guinea pig, hamster, monkey, swine, dog, cat, horse, sheep, goat, cow, and rabbit.
  • the subject is a human.
  • mice were intraperitoneally (ip) injected with PBS or MPTP (25 mg/Kg) for 7 days; which was then followed by orally feeding with olive oil, the ATG-235 solution of Example 1 (2 mL/Kg) , or selegiline (1 mg/Kg) for 14 days. All animals were sacrificed for further study 15 days after the last dose of MPTP.
  • TBS-T Tris-buffered saline
  • tissue samples were incubated with anti-TH, anti-D1R, anti-M1R, anti- ⁇ 7R, anti- ⁇ -synuclein, anti-pTau S396, anti-pTDP43, anti-SIRT1, anti-PGC1, anti-UCP4, and MITOTRACKER TM at room temperature for 2 hours.
  • Tissue samples were further incubated with the secondary antibody ( 488, 633, anti-mouse or anti-rabbit antibody) at room temperature for 1 hour. All antibodies were diluted in 2%non-immune goat serum, in which the serum was dissolved in -containing PBS (PBST) .
  • Tissue samples were incubated with 3, 30-diaminobenzidine (DAB) for 5-10 minutes, and hematoxylin or 4′, 6-diamidino-2-phenylindole (DAPI) was used for nuclear staining.
  • DAB 30-diaminobenzidine
  • DAPI 6-diamidino-2-phenylind
  • the roots of fresh Curcuma longa were cut into thin slices respectively about 0.2 cm in thickness. Dried the root slices in an oven of 55°C, then grounded the dried slices into powders via use of a ball-miller. Filtered the grounded powders through a filter of 400 meshes, thereby producing a dried, filtered Curcuma longa powders independently ⁇ 38 ⁇ m in diameter.
  • Example 2 ATG-235 solution suppressed expression of proteins associated with neuron injury
  • C57BL/6 mice were treated with MPTP to induce neuron injury according to procedures described in the “Materials and Methods” section, then, the MPTP-treated mice were treated with the ATG-235 solution of Example 1, selegiline (which served as a positive control) or a buffer solution (which served as a negative control) , and the levels of various proteins associated with neuron injury in brain tissues, including substantia nigra pars compacta (SNpc) , striatum, hippocampus, and amygdala, were determined. Results are illustrated in FIGs 1 to 4.
  • MPTP suppressed the expression of tyrosine hydroxylase (TH) , type 1 dopamine receptor (D1R) , muscarine acetylcholine type 1 receptor (M1R) , and ⁇ -7 nicotinic acetylcholine receptor ( ⁇ -7R) , but not the level of ⁇ -synuclein, in both SNpc (FIG 1) and striatum (FIG 2) .
  • the ATG-235 solution of Example 1 reversed the MPTP-induced reduction in the levels of TH, D1R, M1R and ⁇ -7R, with its effect being slightly better than that of selegiline.
  • results in this example confirmed that the ATG-235 solution of Example 1 may be useful for treating neuron injury via restoring the respective levels of proteins associated therewith to levels analogous to the normal levels.
  • Example 3 ATG-235 solution of Example 1 improved mitochondrial function of mice suffering from neuron injury
  • SIRT1, PGC1 and UCP4 were independently enzymes that regulated mitochondria biogenesis.
  • the present disclosure provides a novel method for produced a curcuminoid-rich oil extract (i.e., the ATG-235 solution) , in which the curcuminoids dissolved in the oil consist of 25-30% (wt%) of bisdemethoxycurcumin, 25-30% (wt%) of demethoxycurcumin, and 40-50% (wt%) of curcumin.
  • the curcuminoid-rich oil extract may regulate the expression of various proteins associated with neuron injury and enhance mitochondrial function in subjects suffering from diseases associated with neuron injury.
  • the curcuminoid-rich oil extract produced by the present method may serve as a therapeutic agent for preventing and/or treating a subject suffering from diseases associated with neuron injury thereby enhances the life span and life quality of the subject.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un extrait d'huile riche en curcuminoïdes, son procédé de production et son utilisation dans le traitement des maladies associées à des lésions neuronales (par exemple, la démence à corps de Lewy, la maladie de Parkinson et la maladie d'Alzheimer. Dans des modes de réalisation préférés, l'extrait d'huile riche en curcuminoïdes comprend des curcuminoïdes dissous dans une huile comestible, les curcuminoïdes étant constitués de 25 à 30 % (en poids) de bisdéméthoxycurcumine, de 25 à 30 % (en poids) de déméthoxycurcumine, et de 40 à 50 % (en poids) de curcumine.
PCT/CN2021/094802 2021-05-20 2021-05-20 Extrait d'huile riche en curcuminoïdes, procédé de préparation et utilisations associées dans le traitement de maladies associées à des lésions neuronales WO2022241707A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/094802 WO2022241707A1 (fr) 2021-05-20 2021-05-20 Extrait d'huile riche en curcuminoïdes, procédé de préparation et utilisations associées dans le traitement de maladies associées à des lésions neuronales

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/094802 WO2022241707A1 (fr) 2021-05-20 2021-05-20 Extrait d'huile riche en curcuminoïdes, procédé de préparation et utilisations associées dans le traitement de maladies associées à des lésions neuronales

Publications (1)

Publication Number Publication Date
WO2022241707A1 true WO2022241707A1 (fr) 2022-11-24

Family

ID=84140145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/094802 WO2022241707A1 (fr) 2021-05-20 2021-05-20 Extrait d'huile riche en curcuminoïdes, procédé de préparation et utilisations associées dans le traitement de maladies associées à des lésions neuronales

Country Status (1)

Country Link
WO (1) WO2022241707A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6497908B1 (en) * 1999-07-19 2002-12-24 Seiri Oshiro Turmeric-containing cooking oils and fats
WO2007109210A2 (fr) * 2006-03-17 2007-09-27 Herbalscience Singapore Pte. Ltd. EXTRAITS ET PROCÉDÉS CONTENANT DE l'ESPÈCE CURCUMA
CN103960378A (zh) * 2013-01-30 2014-08-06 丰禾生技股份有限公司 含有姜黄素类化合物的食用油组成物及其制法
CN109170890A (zh) * 2018-09-21 2019-01-11 河南科技学院 一种固载姜黄提取物的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6497908B1 (en) * 1999-07-19 2002-12-24 Seiri Oshiro Turmeric-containing cooking oils and fats
WO2007109210A2 (fr) * 2006-03-17 2007-09-27 Herbalscience Singapore Pte. Ltd. EXTRAITS ET PROCÉDÉS CONTENANT DE l'ESPÈCE CURCUMA
CN103960378A (zh) * 2013-01-30 2014-08-06 丰禾生技股份有限公司 含有姜黄素类化合物的食用油组成物及其制法
CN109170890A (zh) * 2018-09-21 2019-01-11 河南科技学院 一种固载姜黄提取物的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE WING-HIN, LOO CHING-YEE, BEBAWY MARY, LUK FREDERICK, MASON REBECCA, ROHANIZADEH RAMIN: "Curcumin and its Derivatives: Their Application in Neuropharmacology and Neuroscience in the 21st Century，", CURRENT NEUROPHARMACOLOGY，, vol. 11, no. 4, 31 December 2013 (2013-12-31), pages 338 - 378, XP093007757 *
SUN NAIYOU, ZHANG WEI: "The extraction of efficient components derived from curcuma and the preparation of oil一based curcumin", CHINA CONDIMENT, no. 10, 31 October 2003 (2003-10-31), pages 27 - 30, XP009541282, ISSN: 1000-9973 *

Similar Documents

Publication Publication Date Title
JP6872805B2 (ja) 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用
NZ544691A (en) Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
RU2668135C1 (ru) Фармацевтическая композиция для лечения и предотвращения дегенеративных неврологических нарушений, которая содержит, в качестве активного ингредиента, смешанный экстракт коры корня пиона полукустарникового, корня дудника даурского и корня володушки или его фракцию
Grimmig et al. Astaxanthin attenuates neurotoxicity in a mouse model of Parkinson’s disease
WO2022052017A1 (fr) Compostions pharmaceutiques et leurs utilisations dans le traitement de l'atrophie musculaire
Wu et al. Four types of traditional Chinese medicine inducing epileptic seizures
Lye et al. Exploring new avenues for modifying course of progression of Alzheimer's disease: the rise of natural medicine
WO2022241707A1 (fr) Extrait d'huile riche en curcuminoïdes, procédé de préparation et utilisations associées dans le traitement de maladies associées à des lésions neuronales
Muralidharan Catharanthus roseus leaves as an anti-diabetic and hypolipidemic agents in alloxan-induced diabetic rats
WO2022052016A1 (fr) Compositions pharmaceutiques et leurs utilisations dans le traitement de la maladie de parkinson
TWI770608B (zh) 藥學組合物及其於治療帕金森氏症之用途
WO2022246586A1 (fr) Utilisation d'un extrait d'huile riche en curcuminoïde pour le traitement d'une lésion pulmonaire aiguë
US11484562B2 (en) Composition for preventing or treating obesity comprising natural mixture extracts
TW202245738A (zh) 富含類薑黃素之油性萃出物、其之製備方法及用以治療神經損傷相關疾病的用途
CN107648482A (zh) 一种用于治疗神经退行性疾病的中药组合物
Malika et al. Captopril modulates behenic acid and L-hydroxyproline to lower blood glucose on high-fat diet and low-dose streptozotocin-induced diabetic-rats
Kareem et al. Evaluation of the hypoglycemic and hypolipidemic effects of aqueous Eleusine coracana seed extract
KR102346790B1 (ko) 콜히친과 메트포르민을 유효성분으로 하는 항비만 치료제
EP2845589B1 (fr) Composition pour la prévention et le traitement de la migraine ou de la douleur neuropathique
US20100267756A1 (en) Pharmaceutical preparation for treating demyelinating diseases of the nervous system; preparation promoting restoration of the myelin sheath of nerve fibers; and a method for treating demyelinating diseases of the nervous system
US7794753B2 (en) Synergistic hepatoprotective composition and a method thereof
KR20110078524A (ko) 인삼 열매 추출물을 함유하는 퇴행성 신경장애 치료용 조성물
HAJI et al. EFFECT OF GARLIC OIL ON SOME BIOCHEMICAL PARAMETERS IN RATS EXPOSED TO HYDROGEN PEROXIDE
Sinha et al. Immunomodulatory Effect of Plant-Based Extracts on Neurodegeneration
Ajmalhussain Assessment of the Neuro-Protective Effects of Combination of Acorus Calamus and Eugenol in Alzheimer’s Animal Model

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21940163

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21940163

Country of ref document: EP

Kind code of ref document: A1